Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 ...

This Progress article describes recent studies showing that the human lipopolysaccharide sensor caspase-4 activates pro-IL-18 and causes vascular leakage by inducing pyroptosis in endothelial cells.

Using its ReSOLVE ® platform, Ventus has identified highly potent and selective small molecules that inhibit caspase-4/5 via a novel allosteric mechanism Despite the therapeutic potential of caspase ...